Key result
A routine invasive strategy reduced the composite of all-cause mortality or myocardial infarction compared with a selective invasive strategy in patients with NSTE-ACS (OR 0.86; 95% CI 0.77-0.96).
Why the study?
Does a routine invasive strategy reduce the composite of all-cause mortality or myocardial infarction in patients with non-ST-elevation acute coronary syndromes compared to a selective invasive strategy?
Meta-Analysis (n=9,650)
Does a routine invasive strategy reduce the composite of all-cause mortality or myocardial infarction in patients with non-ST-elevation acute coronary syndromes compared to a selective invasive strategy?
In patients with NSTE-ACS, a routine invasive strategy significantly reduces the risk of ischemic events, including the composite of mortality or MI, recurrent angina, and future revascularization compared to a selective invasive approach.
Supports routine invasive strategy in NSTE-ACS; confirms mortality/MI reduction across aggregated RCTs.
OBJECTIVES: To perform an updated systematic review comparing a routine invasive strategy with a selective invasive strategy for patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) in the era of stents and antiplatelet therapy. BACKGROUND: Recent meta-analyses comparing both strategies have shown conflicting results. METHODS: Electronic databases were searched for randomized trials that compared a routine invasive strategy (i.e., routine coronary angiography +/- revascularization) versus a selective invasive strategy (i.e., medical stabilization and coronary angiography +/- revascularization if objective evidence of ischemia or refractory ischemia) in patients with NSTE-ACS. Summary odds ratios (OR) were primarily constructed using Peto's model. RESULTS: Twelve trials with 9,650 patients were included. Compared with a selective invasive strategy, a routine invasive strategy was associated with a reduction in the composite of all-cause mortality or myocardial infarction (MI) [OR: 0.86, 95% confidence interval (CI) 0.77-0.96] at a mean follow-up of 39 months, primarily due to a reduction in the risk of MI (OR: 0.78, 95% CI: 0.68-0.88). The risk of all-cause mortality was non-significantly reduced with a routine invasive strategy (OR: 0.88, 95% CI: 0.77-1.01). The risk of recurrent angina was reduced with a routine invasive strategy (OR: 0.55, 95% CI: 0.49-0.62), as well as the risk of future revascularization procedures (OR: 0.35, 95% CI: 0.30-0.39). CONCLUSION: In patients with NSTE-ACS, a routine invasive strategy reduced the risk of ischemic events, including the risk of mortality or MI. Routine invasive therapy reduced the risk of recurrent angina and future revascularization procedures.
No takes yet. Share an insight, caveat, or question.
Elgendy et al. (2016) conducted a meta-analysis in non-ST-elevation acute coronary syndromes (NSTE-ACS) (n=9,650). Routine invasive strategy vs. Selective invasive strategy was evaluated on composite of all-cause mortality or myocardial infarction (MI) (OR 0.86, 95% CI 0.77-0.96). A routine invasive strategy reduced the composite of all-cause mortality or myocardial infarction compared with a selective invasive strategy in patients with NSTE-ACS (OR 0.86; 95% CI 0.77-0.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: